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Objective. Clinical validation of a chemoresponse assay was recently published, demonstrating a signiﬁcant
increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor
was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time
of ovarian cancer recurrence from the payer's perspective.
Methods. Using a Markov state transition model, patient characteristics and survival data from the recent
clinical study, the cumulative costs over the study horizon (71 months) for both the baseline (no assay) and
intervention (assay consistent, hypothetical) cohorts were evaluated.
Results. The assay consistent cohort had an incremental cost effectiveness ratio (ICER) of $6206 per life year
saved (LYS), as compared to the baseline cohort. Cost-effectiveness was further demonstrated in platinum-
sensitive and platinum-resistant populations treated with assay-sensitive therapies, with ICERs of $2773 per
LYS and $2736 per LYS, respectively.Conclusions. The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancer
patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Over 70% of newly diagnosed cases of epithelial ovarian cancer
(EOC) present at an advanced stage (stages III–IV), which accounts for
the poor prognosis. Advanced stage EOC patients have amedian survival
of 44 months and a ﬁve year survival of 35% to 38% [1–3]. In the United
States, the standard of care treatment for patients with advanced stage
EOC is cytoreductive surgery, followed by postoperative platinum-15203, United States. Fax: +1
. This is an open access article underbased chemotherapy [4]. Despite complete clinical remission in 80% to
90% of patients undergoing the standard of care ﬁrst-line treatment,
70% to 90% of them relapse, and the majority who relapse experience
multiple recurrences that can often be induced into remission by further
surgery and chemotherapy [5].
While treatment guidelines for the primary occurrence of advanced
stage EOC recommend numerous platinum-based combination thera-
pies, an even greater number of treatment regimens are recommended
for recurrent disease. Currently, nearly 10 different platinum-based
therapies are recommended for treatment of patients with platinum
sensitive (PS) recurrent disease (experiencing recurrence greater than
6months followingﬁrst-line treatment), andover 20different therapiesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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platinum resistant (PR) recurrent disease (experiencing recurrence
within 6 months following ﬁrst-line treatment) [6], with little to no
guidance on how to select among the options. Thus, in the absence of
speciﬁc directives beyond the primary setting, treatment choices for re-
current EOC patients are made empirically [7].
Despite historical debate regarding their clinical use, chemoresponse
assays are a promising method for evaluating individual patient re-
sponse to a variety of chemotherapy regimens and are gaining clinical
validity. A previous economic analysis showed cost savings in a hypo-
thetical cohort of patients treated with assay sensitive therapies [8],
and recent multi-site clinical studies reported an association between
survival and treatment with assay-sensitive therapies in advanced
EOC, thuswarranting aneconomic analysis of this assay based onpatient
clinical outcomes. A study of 276womenwith stage III–IV primary ovar-
ian, fallopian or peritoneal cancer established that the chemoresponse
assay result for carboplatinwas the only covariate that could identify pa-
tients who are platinum resistant (PR) prior to ﬁrst-line treatment with
a platinum-based regimen. Patients with a resistant assay to carboplatin
experienced disease progression at almost twice the rate of those who
were non-resistant [9]. Additionally, a prospective, non-interventional
study evaluated the use of the chemoresponse assay in 262 recurrent
or persistent EOC patients. Patients empirically treated with assay-
sensitive therapies (physicians were blinded to assay results at the
time of treatment selection) experienced signiﬁcantly improved out-
comes over those treated with assay-resistant therapies — a 50% im-
provement in progression-free survival (PFS) and a 14 month
improvement in median overall survival (OS) [10]. Further analysis of
this cohort suggests that the chemoresponse assay may be a predictive
marker, capable of discerning response to speciﬁc treatments [11]. Clin-
ical utility of the assay was also demonstrated in a comparative study
wherein the OS of assay-informed primary EOC patients [12] was com-
pared to non-assay-informed (control) patients, collated from four
large clinical studies [1–3,13]. Despite moderately worse prognostic
clinical factors, patients in the assay-informed arm experienced a 10%
improvement in median OS, as compared to the control arm. Further-
more, the median OS in patients treated with assay-sensitive therapies
was 65% longer (72 vs. 44 months) than that in the control arm [14].
Based on these observations, the current analysis sought to investi-
gate the relative cost effectiveness of an assay-informed second line
treatment regimen relative to assay-uninformed, empiric standard of
care, assuming the payer's perspective. Using a Markov state transition
model and integrating patient characteristics and clinical outcomes
from a recent clinical study, the cost effectiveness of the assay will be
evaluated for recurrent ovarian cancer patients, as well as subsets of
platinum sensitive and platinum resistant patients.
Methods
Model
This analysis compares two hypothetical cohorts of patients with re-
current EOC who have undergone a secondary surgery or paracentesis,
based on the distribution of patients by their assay outcome, as reported
in a recent clinical study [10]. In the baseline cohort, patients were
assigned to second line treatments using standard clinical practices,Table 1
Classiﬁcation of study patients by platinum sensitivity and assay result (N = 262) [10].
Platinum sensitivea and
assay sensitiveb
Plati
assay
Actual clinical assignment during blinding 17% 38%
Potential clinical assignment 32% 23%
a Platinum sensitivity was the result observed clinically, prior to the beginning of the study.
b A patient was classiﬁed as “assay sensitive” if at least one therapy tested by the assay had
c A patient was classiﬁed as “assay resistant” if all therapies tested by the assay has either anwithout consideration of chemoresponse assay results. The comparator
cohort is assay consistent, meaning that the chemoresponse assay was
employed (and yielded successful results) and patients were treated
with sensitive second line therapies identiﬁed by the assay. In the refer-
enced study, 28% of the patients received an on-study treatment that
was also a sensitive (S) treatment per the chemoresponse assay
(Table 1, row 1) [10]. Patients were also tallied by assay results to ther-
apies other than the on-study treatment and by their platinum sensitiv-
ity status (Table 1, row 2). Fifty-four percent of the patients had at least
one S treatment identiﬁed by the assay and could have received an S
treatment in this study; this distribution was used to deﬁne the assay
consistent cohort.
Using the survival outcomes reported in the referenced study [10],
as well as the distributions given in Table 1, a Markov state transition
model was built with the following three states: State 1: Remission 2,
State 2: Recurrence 2 &Other and State 3: Death (Fig. 1). State 2 encom-
passes all events from the onset of a second recurrence and preceding
death. The cycle length in the model was set at one month and the
time horizon at 71 months; the maximum duration of follow-up in
Rutherford et al. OS was deﬁned as the length of time from the start of
recurrence chemotherapy until death or last contact (for censored pa-
tients) [10]. ThemeanOSwas estimated as the area under the estimated
cohort survival curve up to 71 months.
To estimate p11, p21 and p31 (Fig. 1), a marginal Cox proportional
hazard regression [15] was used to model the time from remission to
disease progression and from remission to death vs. platinumsensitivity
status and the assay results. To estimate p22 and p32, a conditional pro-
portional hazard regression for recurrent events [16] was used tomodel
the time from disease progression to death. The output from both
models is reported in Table 2. These two survival regressions provide
probability estimates for the Markov transition matrices in each of the
four possible patient groups of platinum sensitivity and assay outcome.
Using the weights in Table 1, the weighted sum of the four transition
matrices makes up the ﬁnal transition matrix in each cohort. Details
on the computation of the cohort transition probabilities are provided
in the Supplementary materials.
The Markov transition model enables survival estimates in each co-
hort, over the study horizon. Furthermore, this model is used to esti-
mate the average cost per patient in each cohort over the entire time
horizon.
Costs
The major costs associated with the treatment of recurrent EOC and
considered for this analysis were divided into ﬁve categories: cost of the
chemoresponse assay, cost of surgery, cost of chemotherapy, cost of ad-
verse events and toxicities, and cost of end of life care. The main source
for the cost data in this analysis was the published peer-reviewed liter-
ature, although costs of chemotherapy and paracentesis reﬂect current
Medicare pricing. It was assumed that both arms incur the same cost
per surgery, end of life care and treatment of toxicities, although the
published cost data are more applicable to the baseline cohort, as op-
posed to the assay consistent cohort. This is a conservative strategy fa-
voring the baseline cohort, since it is unlikely that the prevalence and
cost per treatment for toxicity, surgery and end of life care are higher
in the assay consistent group. Additionally, all cost ﬁgures related tonum sensitivea and
resistantc
Platinum resistanta and
assay sensitiveb
Platinum resistanta and
assay resistantc
11% 34%
22% 23%
an S result.
IS or an R result.
Fig. 1. A three state Markov transition model for recurrent EOC. The three states are State
1: Remission 2 (immediately following a second line treatment at the time of the ﬁrst re-
currence), State 2: Recurrence 2 & Other (all events from the onset of a second recurrence
and preceding death) and State 3: Death.
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adjusted for inﬂation.Cost of the chemoresponse assay
The cost of the chemoresponse assay is incurred only by the patients
in the assay consistent cohort. Patients in this cohort are assumed to
have their tumors evaluated prior to the beginning of second line of
therapy (i.e. at the time of the ﬁrst recurrence). The average cost of
the assay (ChemoFx®, Helomics™ Corporation, Pittsburgh, PA) is
$434.65 per therapy tested. On average, 10 therapies are tested per
tumor, at a cost of $4346.50, which is the cost ﬁgure included in this
analysis.Cost of surgery
To reﬂect the clinical cohort [10], 93% of patients in each of the base-
line and assay consistent cohorts were assumed to have undergone a
secondary cytoreductive surgery, while 7% in each cohortwere assumed
to have undergone paracentesis. Both surgery and paracentesis were
clinically indicated, and excess tissue or ﬂuid was available for use in
the chemoresponse assay; no additional procedures were required to
fulﬁll tissue requirements for the assay. The cost of surgery, inclusive
of hospital and physician charges incurred during the surgical hospital-
ization, ranged from$21,914 to $33,678 in 2009, dependingon the com-
plexity of the surgery [17]. The midrange of this interval ($27,796) was
used in the current model, adjusted for inﬂation to 2013 dollars
($30,182). Using current Medicare pricing, the cost of paracentesis
ranges from $193.08 to $597.48, depending upon the use of imaging
as well as the facility in which the procedure takes place [18]. TheTable 2
Cox proportional hazard regressions to model the time from remission to disease progression
Covariates Marginal model
HR (n = 262)
Platinum sensitivity status (PS vs. PR) 0.60
Chemoresponse assay result (S vs. IS or R) 0.66
Event stratuma 0.09
a In the marginal model, “Event stratum”was a categorical variable denoting two possible e
model, “Event stratum” was a categorical variable denoting two conditional events for each paaverage price among the various options was used in the current
model ($395.96).
Cost of chemotherapy
All patients in the current model were treated with a second line
therapy at the time of the ﬁrst recurrence. The costs associated with 6
cycles of each chemotherapy regimen, as well as the associated admin-
istration costs (in the physician ofﬁce setting), were estimated using
current Medicare physician fee schedule for administration payments
and drug pricing database for chemotherapy agents [19,20]. Doses
were calculated assuming a body surface area of 1.8 m2, serum creati-
nine of 0.9 mg/dL, weight of 170 lb, height of 62 in., and age of 63
years. To estimate the cost of the second line chemotherapy in the base-
line cohort, the distribution of administered therapies in the referenced
cohort [10] and the costs calculated for the baseline cohort were used
(Supplementary Table S1). Thus, the average cost of six cycles of salvage
chemotherapy in the baseline cohort was estimated at $7990 in current
dollars. The cost of the second line chemotherapy in the assay consis-
tent cohort was estimated by the average cost of all therapies in the
highest category of assay sensitivity for each patient; this cost was
$4957 in current dollars.
Cost of major adverse events and toxicities
Neutropenia and anemia are two major hematologic adverse events
(AEs) related to chemotherapy in EOC. Among the platinum-based ther-
apies, the incidence of grade 3/4 anemia is 1% for carboplatin and 11%
for cisplatin, while for the other therapies the incidence ranges from
5% for pegylated liposomal doxorubicin (PLD) to 28% for topotecan
[21]. Neutropenia is common with nonplatinum therapies and occurs
in 12% of patients administered PLD, 45% of patients administered
etoposide and 77% of patients administered topotecan [21]. The current
analysis assumes a conservative 5% rate of grade 4 anemia in both co-
horts associated with second line chemotherapy and a 3% rate of
grade 4 neutropenia. The cost of hospitalization for grade 4 neutropenia
and anemia was estimated at $9500 and $3500, respectively, assuming
$8000 for the cost of hospitalization for diagnosis and $25,000 for the
cost of hospitalization and subsequent death, while an additional 5%
are hospitalized for other reasons [22]. Since these cost ﬁgures were re-
ported for the year 2013, they have not been further adjusted.
Cost of end of life care
The average cost per patient within 60 days of end of life (EOL) dif-
fers dramatically based on the length of time spent in hospice [23]. In
a group of patients from 1999 to 2003, the average cost per patient for
spending 10 to 60 days in hospice was $15,164. In contrast, the average
cost per patient for the same healthcare resources for patients spending
10 days or less in hospice was $59,319 [23]. Based onMedicare records,
the percentage of advanced stage ovarian cancer patients receiving hos-
pice care was 74.9% in 2005, of which 26.2% spent seven days or less in
hospice [24]. This analysis uses an EOL care rate of 74.9% and conserva-
tively assumes that 26.2% of these patients spend 10 days or less in hos-
pice and incur an average EOL cost of $75,102 per patient in 2013. For
the patients spending 10 to 60 days in hospice, an average cost of
$19,198 per patient will be assumed.or to death, as compared to platinum sensitivity status and assay results.
Conditional model
p-Value HR (n = 262) p-Value
b0.0001 0.68 0.0001
0.0052 0.65 0.0003
b0.0001 0.71 0.0011
vents for each patient: disease progression and death since remission. In the conditional
tient: disease progression since remission and death since disease progression.
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The relative cost effectiveness of the intervention is expressed by the
incremental cost effectiveness ratio per life-year saved (ICER/LYS),
which is the ratio of the difference in the average costs per patient to
the difference in the mean overall survivals. The standard threshold
for a healthcare intervention to be deemed cost-effective is an expendi-
ture of between $50,000 and $100,000 per additional year of life saved
[25]. Keeping the costs for surgery, individual chemotherapies, EOL
care and AE treatment constant between both cohorts, the model re-
sults are affected only by the cost of chemoresponse assay and survival
outcomes. First, the results are presented in the reference cost effective-
nessmodel (Table 3). To account for the uncertainty in theHR estimates
associated with the assay and its impact on the ICER/LYS, the range in
the ICER/LYS was estimated by independently sampling 1000 times
from each of the two 95% CI of the HRs for the assay. Several stratiﬁed
analyses for the reference model are also reported. To assess the sensi-
tivity of the model due to the cost of chemotherapy, the scenario
when the oncologist chooses the least expensive treatment within the
highest category of sensitivity for each patient in the assay consistent
cohort was also investigated.
Results
The Markov model median OS and mean OS in the baseline cohort
were estimated at 25 and 29.8 months, respectively. By comparison,
the median OS and mean OS in the referenced clinical study were 26.5
and 31 months, respectively [10]. In the assay consistent cohort, the
Markov model median OS was 28 months and the mean OS was 32.3
months. The modeled average costs per patient in the baseline and
assay consistent cohorts were $39,610 and $40,903, respectively. The
referencemodel yielded an ICER of $6206 per LYS for the study horizon
(Table 3).When narrowing the comparison to the subgroup of platinum
sensitive and assay sensitive patients, the ICER is $2773per LYS,while in
the platinum resistant and assay sensitive patients, the ICER is $2736
per LYS (Table 3). When choosing the least expensive therapy within
the patient's highest category of sensitivity, the average cost of six cycles
of chemotherapy becomes $1759 in the assay consistent cohort. Intro-
ducing this change alone in the model makes the chemoresponse
assay a dominant intervention (Supplementary Table S2). The model
is sensitive to the cost of chemotherapy, but the upper bound of this
source of sensitivity has been tested by assuming the same unit cost of
therapy for both cohorts in the reference model (Supplementary
Table S1 and Table 3). Despite this conservative assumption, the inter-
vention remains cost effective at the lower $50,000 threshold.
Discussion
Treatment decisions for patients with recurrent EOC are largely
guided by response to previous therapy, incident and anticipated toxic-
ity, performance status and disease distribution. However, among anyTable 3
Results for the reference cost effectiveness model. The range in the ICER/LYS was estimated by
Full cohort Average cost per patient
Median overall survival
Mean overall survival
Platinum sensitive, assay sensitive subgroup Average cost per patient
Median overall survival
Mean overall survival
Platinum resistant, assay sensitive subgroup Average cost per patient
Median overall survival
Mean overall survivalindividual cohort, the speciﬁc chemotherapy choice is largely empiric,
reﬂecting numerous acceptable regimens. Currently, the most utilized
clinical covariate in making individualized treatment decisions is treat-
ment free interval, which informs the use of platinum-based therapy in
platinum sensitive patients. However, as with most clinical covariates,
its accuracy is not absolute, and additionalmeasures of patient response
may be beneﬁcial in further personalizing treatment strategies. Despite
several clinical drug trials that have sought to identify preferable treat-
ments, no clear standard of care has emerged, further demonstrating
the need for decision support tools in this population where multiple
rounds of treatment (due to multiple recurrences) are commonplace.
The current study employs a Markov model to hypothetically com-
pare the cost of treatment decisions that adhere to chemoresponse
assay results at the time of second line therapy in patients with recur-
rent EOC with those that are made empirically, in the absence of
chemoresponse testing. Typically, a healthcare intervention, such as a
chemoresponse assay, is considered to be cost effective if the compre-
hensive cost of its use is less than $100,000 per additional life year
saved [25]. In the current study, use of and adherence to chemoresponse
assay results yield an ICER of $6206 per additional life year saved, sug-
gesting that the assay intervention is cost-effective even at a conserva-
tive $50,000 threshold. Furthermore, in analyses of patients with an
assay-sensitive result for at least one therapy, the ICER dropped to
$2773 per LYS in PS patients and to $2736 per LYS in PR patients,
where the need for decision support tools is greater due to poorer prog-
nosis. While the current study examines cost effectiveness in the recur-
rent EOC setting, future studies are plannedwhichwill evaluate the cost
effectiveness of this chemoresponse assay across the entire treatment
duration of patients with advanced EOC, accounting for its inﬂuence in
both the primary and recurrent settings.
Although thebaseline cohortwasdesigned tomimic a patient cohort
[10], and in many respects this goal wasmet (e.g. the model-based me-
dian OS in the baseline cohort was comparable to the median OS ob-
served clinically), the assay consistent cohort is hypothetical, with no
equivalent observed patient group for comparison. The survival out-
come in the assay consistent cohortwasmodeled based on the observed
survival difference between the patients treated with assay S and R
therapies [10] and a hypothetical reassignment of all patients to be
treated with an assay S therapy, consistent with the assay results for
each patient. The model then assumed that the empirical assignment
to treatment (baseline cohort) (Table 1, row 1) and the assay consistent
reassignment (assay consistent cohort) could be generalized at the pop-
ulation level. Additionally, themodel assumed that the observed surviv-
al difference between patients treated with assay S and assay R
treatments may be generalized to the greater population.
Since physicianswere blinded to assay results in the baseline cohort,
there is no concern of bias in the empirical treatment assignments in
that cohort (i.e. bias toward ‘guessing’ the assay assignment). Conse-
quently, the treatment assignments in the assay consistent cohort
were independent of those made empirically in the baseline cohort.
However, in this analysis, one potential source of bias is inclusion ofindependently sampling 1000 times from each of the two 95% CI of the HRs for the assay.
Baseline cohort Assay consistent cohort ICER/LYS (range)
$39,610 $40,903
25 months 28 months
29.8 months 32.3 months
$6206
($4578–$10,208)
$39,514 $40,762
35 months 43 months
38 months 43.4 months
$2773
($1535–$5982)
$39,638 $40,892
23 months 28 months
26.8 months 32.3 months
$2736
($1407–$6720)
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who exhibit assay R to all tested treatments. In the referent clinical co-
hort only 10% of patients were sensitive to all single agent treatments
and 8% were resistant to all [10]. To date, there is no established meth-
odological framework in place for conducting efﬁcient randomized clin-
ical trials for multi-treatment markers such as this chemoresponse
assay. This is a new frontier in the biostatistics and marker validation
ﬁelds that is currently being explored [26,27].
In this study, all unit costs were held constant between the baseline
and assay consistent cohorts, with the exception of the cost of the assay
in the assay consistent group. The current analysis reveals that the
chemoresponse assay may impact the cost of treatment in several
ways. Given the association between treatmentwith an assay S therapy
and prolonged OS [10], the assaymay reduce or delay the cost of certain
treatment aspects, as is the case with EOL care costs. The assaymay also
optimize the cost of treatment by allowing the physician to not only se-
lect an effective therapy, but also select a less expensive chemotherapy
among those that are identiﬁed as S, with the potential for the assay in-
tervention to be cost-saving (Supplementary Table S2). Of note, doxoru-
bicin, the most expensive chemotherapy included in this analysis, was
administered 20% of the time in the baseline cohort while the assay in-
dicated it as effective only 8% of the time in the assay consistent cohort
(data not shown). Although not captured in this analysis, the use of a
chemoresponse assay in making treatment decisions may potentially
reduce toxicities and their associated costs, as well as improve the pa-
tients' overall quality of life, by reducing the number of ineffective treat-
ment rounds. The cost effectiveness of the assay may be further
enhanced when accounting for these differences. However, the current
study assumes identical toxicity proﬁles across both cohorts, but a
change in the therapy distribution could entail a favorable change in
the toxicity and AE proﬁles (type, frequency) toward those patients
treated with effective agents, thereby avoiding toxicities, costs, and fur-
ther compromised quality of life associated with ineffective treatments.
Despite these limitations, this analysis was able to estimate an upper
bound in the ICER/LYS that still qualiﬁes the intervention as cost-
effective.
Given the potential impact on OS and resulting cost-effectiveness in
both PS and PR patients, a chemoresponse assay should be considered
when developing personalized treatment plans for patients with recur-
rent EOC.
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